Understanding Hematological Toxicities Using Mathematical Modeling

Clin Pharmacol Ther. 2018 Oct;104(4):644-654. doi: 10.1002/cpt.1080. Epub 2018 May 1.

Abstract

Balancing antitumor efficacy with toxicity is a significant challenge, and drug-induced myelosuppression is a common dose-limiting toxicity of cancer treatments. Mathematical modeling has proven to be a powerful ally in this field, scaling results from animal models to humans, and designing optimized treatment regimens. Here we outline existing mathematical approaches for studying bone marrow toxicity, identify gaps in current understanding, and make future recommendations to advance this vital field of safety research further.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacokinetics
  • Bone Marrow / drug effects*
  • Bone Marrow / pathology
  • Bone Marrow / physiopathology
  • Cell Lineage
  • Dose-Response Relationship, Drug
  • Hematologic Diseases / chemically induced*
  • Hematologic Diseases / pathology
  • Hematologic Diseases / physiopathology
  • Hematopoiesis / drug effects*
  • Hematopoietic Stem Cells / drug effects*
  • Hematopoietic Stem Cells / pathology
  • Humans
  • Models, Biological*
  • Risk Assessment
  • Toxicity Tests / methods*

Substances

  • Antineoplastic Agents